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14 Among breast cancer survivors, specifically, research has suggested that up to 51% of women report at least 1 unmet need in the first 5 years following treatment. 7 When these issues are not adequately addressed by providers, they can have an impact not only on the psychosocial and physical functioning of cancer survivors, but on adherence to follow-up recommendations, such as aromatase inhibitor (AI) use. 15 Which symptoms are most likely to result in unmet need following treatment, however, is less clear, and the presence of symptoms may not indicate a desire for assistance. For example, Osse and colleagues 16 found that although Dutch cancer patients reported an average of 37 symptoms and concerns during treatment, they desired additional assistance with only 8. Similarly, Cheng and colleagues 7 found that although 88% of Singaporean breast cancer patients reported at least one bothersome symptom in the 5 years following treatment, just 51% reported at least one unmet need. It seems that physical and psychosocial symptoms vary over the disease trajectory, and that unmet need is greatest in the year following treatment and decreases over time unless there is a recurrence. 17 Thus, early supportive care may be essential to maintaining or improving QoL. Unfortunately, the issue of "don't ask, don't tell" and a focus on cancer surveillance and recurrence avoidance may prevent many patients from receiving the assistance they desire for their symptom distress during clinical encounters. Patient-reported outcome (PRO) assessment may be one means of addressing this problem as even highly compromised patients have the ability to respond to selfreport questionnaires concerning their current symptom experiences. 18 This study emerged from a clinical initiative to improve patient care at end of treatment and is an initial step in examining a means of improving patient assessment and, ultimately, patient outcomes. The purpose of the present study was to examine the symptoms and concerns of recently treated breast cancer patients, level and type of unmet need, demographic and treatment variables associated with concerns and unmet need, and the relationship of symptoms and unmet need to the QoL achieved by patients.
Method and materials

Participants
Participants were consecutive female patients at a single facility who had completed initial or primary therapy for breast cancer within the previous 12 months. Eligibility included age of at least 18 years, confirmed diagnosis of ductal carcinoma in situ (DCIS) or nonmetastatic breast cancer, scheduled for a follow-up survivorship visit, and the ability to read, write, and understand English. Current receipt of targeted or hormonal therapy was allowed.
Procedure
Following receipt of approval by the facility's Institutional Review Board and Clinical Trials and Scientific Review Board, clinic schedules were screened for potentially eligible participants. Successive eligible participants were approached during their scheduled visit, the study explained, and informed consent obtained. Participants were then provided with a questionnaire packet to complete before meeting with their provider. Participants who were not able to complete the questionnaire before their appointment took the materials home with them and were asked to return them by mail. Up to 3 reminder calls were made if materials were not received within 2 weeks.
Measures
Demographics included age, race, ethnicity, marital status, education level, household income, and menopausal status. Disease and treatment variables were abstracted from charts and included time since diagnosis, stage at diagnosis, and treatments received.
Symptoms and unmet need were assessed using an investigator-developed questionnaire that lists 19 symptoms found to have a prevalence of >10% in 3 separate samples of breast cancer patients and survivors (N = 711). We use the terms symptoms and concerns interchangeably, because some represent symptoms of a given disorder whereas others represent concerns an individual may have. Concerns and symptoms included Fatigue, Pain, Insomnia, Numbness or Tingling, Aching Joints, Aching Muscles, Swelling, Depression, Difficulty Concentrating, Memory Difficulties, Anxiety, Body Image Problems, Problems with Urination, Vaginal Dryness, Decreased Sexual Interest, Hot Flashes, Night Sweats, and Weight Gain. Symptoms and concerns were presented and severity was rated on a scale of 0-5 (0, Did Not Experience; 5, As Bad As Possible). A symptom was considered present if it was rated at ≥1. For each symptom scored present, participants reported whether or not they needed additional help with the symptom in a dichotomous manner. Symptoms rated as present and for which individuals desired additional assistance were considered currently unmet needs.
QoL was assessed using the Medical Outcomes Study Short Form-12. 19 The SF-12 is an extensively validated instrument that has been widely used as an alternative to the more burdensome SF-36 20 and shown to account for more than 90% of the variance in SF-36 physical and mental health summary measures.
Statistical analysis
Proportions and exact confidence intervals 21 are presented to describe presence of concerns or symptoms (ie, those rated as having a severity ≥1). Associations between continuous variables are presented using Pearson correlation coefficients. Associations between continuous and categorical variables are presented as either point biserial correlations, t-tests, or analysis of variance (ANOVA) as appropriate.
Results
Participant characteristics
Of 267 eligible patients, 226 were approached for recruitment and 164 (76.6%) were ultimately recruited and provided adequate data for analysis. Primary reasons for nonparticipation were inability to approach because the patient failed to show for an appointment (n = 21) and refusal to consent (n = 21). Most of the participants were white (72%), middle-aged (mean, 54.5 years), married or in a marriage-like situation (65%), employed (61.6%) with at least a college education (64.6%) and an annual household income of greater than $60,000 (56.5%; Table 1 ). Overall, participants reported physical QoL similar to but below normative values of 50 (mean, 48.0 [SD, 8.2]; P < .001) and mental health QoL above national norms (mean, 53.6 [SD, 11.3]; P < .001; both t ≥2.96). On average, women were 10.8 months from diagnosis and 5.2 months from end of acute treatment. e majority of women were diagnosed with stage 0 or I breast cancer (57.5%), and had received surgery (99%), chemotherapy (60.4%), radiotherapy (65.4%), and/or endocrine therapy (77.5%).
Presence and severity of symptoms
On average, participants reported 11.5 (SD, 4.44) symptoms (range, 0-19; Table 2 ). e most commonly reported symptoms included fatigue (90%), insomnia (75%), hot ashes (73%), and aching joints (70%). ANOVA demonstrated that number of symptoms reported was positively associated with stage at diagnosis (F 3,156 = 5.29, P = .002) with individuals with stage III breast cancer reporting almost twice as many symptoms as those with DCIS (mean, 14.38 vs 7.36, respectively). Similarly, those who received chemotherapy reported signi cantly more symptoms than chemonaïve women (F 1,148 = 4.15, P < .05). Number of symptoms was inversely but weakly related to time since end of treatment (r = -.17, P = .04) and not signi cantly related to age, receipt of radiation therapy, ovarian failure following treatment or receipt of AIs (all P ≥ .09).
e most bothersome symptoms di ered slightly from the most common symptoms, and symptom severity (scale of 0-5: 0, Did Not Experience; 5, As Bad As Possible) was highest for aching joints (mean, 2.94), decreased sexual interest (mean, 2.83), hot ashes (mean, 2.82), and vaginal dryness (mean, 2.76). Average severity for these 4 most bothersome symptoms was positively related to staging at diagnosis, and receipt of AIs (all P < .05), and marginally related to receipt of radiation therapy (P = .053). Severity for the 4 most bothersome symptoms was unassociated with age, time since diagnosis or treatment, or receipt of chemotherapy (all P > .12).
Average severity across all symptoms was positively Original Report related to staging at diagnosis and receipt of chemotherapy using ANOVA (all F > 5.50, all P < .02), but weakly and negatively related to age (r = -.19, P < .05). Average severity was unrelated to time since diagnosis or end of treatment, menopausal status, receipt of radiation therapy, or use of AIs (all P > .20).
Unmet need
We examined unmet need for assistance with symptoms from two basic perspectives, the proportion of the overall sample expressing an unmet need, and the proportion of patients experiencing a symptom who reported unmet need. e former represents the level of unmet need within the clinic and is in uenced by the prevalence of each symptom within the sample, while the latter allowed us to determine which symptoms resulted in the most desire for assistance. Across the sample, participants reported an average of 2.6 (SD, 3.90) unmet needs (range, 0-15). e distribution of unmet needs was positively skewed (Table 3) , with 49% of the sample reporting no unmet need and 25% reporting 4 or more unmet needs. Overall, the sample most common unmet needs were aching joints (24%), fatigue (23%), insomnia (20%), and weight gain (19%). Symptom severity by unmet need status among individuals experiencing a given concern is shown in Table 4 . As can be seen, in all cases except that of weight gain, those women who wanted additional assistance rated severity signi cantly higher than those who did not want assistance.
e number of unmet needs was unrelated to staging at the time of diagnosis, ovarian failure after diagnosis, age, time since diagnosis or treatment, or receipt of chemotherapy (all P > .33). Number of unmet needs was related to receipt of AIs such that women receiving AIs reported more unmet need (mean, 3.25) than did those who were not receiving AIs (mean, 2.01, F 1,160 = 4.29, P = .040). We also examined which symptoms were more likely to result in unmet need. Among participants experiencing a given symptom, weight gain (50%), aching joints (45%), numbness in limbs (44%), and urinary di culties (43%) were the most likely to result in unmet need.
Quality of life, symptoms, and unmet need
Physical QoL on the SF-12 was not associated with stage www.jcso-online.com
Original Report at diagnosis, receipt of chemotherapy or radiotherapy, or time since diagnosis (all P > .41). Physical QoL was modestly associated with time since end of treatment (r = 0.18, P < .05), and with menopausal status (F 2,116 = 5.20, P < .005) such that women who were menopausal following treatment reported the lowest QoL. ere was a trend for physical QoL to be associated with negatively receipt of AIs and (P < .07). Mental health QoL on the SF-12 was not associated with stage at diagnosis, receipt of chemotherapy or radiotherapy, time since diagnosis or end of treatment, receipt of AIs, menopausal status, or age (all F < 3.52, all P > .46). Both physical and mental health QoL were negatively associated with number of concerns (r = -.46, r = -.43, all P < .001, respectively), average severity of concerns (r = -.44, r = -.58, all P < .001, respectively), and number of unmet needs (r = -.17, r = -.41, all P < .05, respectively).
Discussion
is study demonstrates that breast cancer survivors within 1 year of the end of primary treatment report multiple symptoms as well as unmet needs for which they desire additional assistance. Half of the sample reported 12 or more symptoms, and 1 of 4 reported at least 15. Unmet needs, however, were lower and participants wanted assistance with an average of only 2.6 concerns in the year following primary treatment, though this varied greatly.
Among individuals reporting a given symptom, intervention was most likely to be desired for weight gain, aching joints, numbness, tingling in limbs, and problems with urination. Between 40%-50% of those experiencing these issues desired intervention of some sort near the end of treatment. Importantly, these are primarily subjective concerns that may be overlooked in general clinical care. About Severity rated on a scale of 0-5 (0, Did Not Experience; 5, As Bad as Possible). A symptom was considered present if it was rated at ≥1.
one-fifth to one-quarter of the entire sample of breast cancer survivors reported unmet need for intervention with aching joints, fatigue, sleep disturbance, and weight management. At the population level, conservatively assuming 295,000 new cases 1 of invasive and noninvasive breast cancer a year and a 90% survival rate, it could be estimated that there would be more than 53,100 breast cancer survivors annually who desire intervention for any one of those symptoms.
The degree to which patients experiencing a moderate level of severity for a given concern do not report a desire for assistance is also noteworthy ( Table 2 ). For example, among individuals experiencing depression or anxiety at a level of 3:5 or greater, the majority (63% and 60%, respectively) did not desire intervention despite effective treatments being available 22 even among breast cancer patients. 23 Whether this lack of desire for assistance represents patient preferences regarding treatment, existing but potentially inadequate treatment, or a need for patient education is not apparent from these data, although it may signify a need for discussion and evaluation of symptoms during the clinical encounter. Regardless, assessment of patient-reported concerns, such as those investigated here, may be one means of improving outcomes and reducing symptom burden. The most severe symptoms included aching joints, hot flashes, decreased sexual interest, and vaginal dryness. All of these have been previously associated with receipt of AIs. 24, 25 We found that the severity of these symptoms was related to stage at diagnosis, becoming menopausal after diagnosis, and receiving AIs. Between 25%-45% of those experiencing these symptoms desire intervention. Unmet needs associated with receiving AIs, in particular, may represent an important target, as these symptoms have been shown to predict discontinuation of AI therapy 26, 27 and adherence to AIs predicts survival. 28 This also highlights a need to explicitly inquire about AI-related symptom burden, as these symptoms are under-recognized by providers treating breast cancer survivors with AIs. 29 Unmet need for symptom distress among breast cancer survivors represent a meaningful target for improving the QoL experienced by this population. The number of symptoms reported accounted for 16%-21% of the variance in mental and physical QoL, and severity of those concerns accounted for at least this much. Moreover, the number of unmet needs accounted for 34% of the variance in mental health QoL. Thus, reducing symptom burden and addressing unmet needs may be a means of improving QoL for the majority of breast cancer patients who will survive initial treatment. Moreover, those women receiving AIs reported a greater number of unmet needs, suggesting another opportunity to improve outcomes.
It is interesting to note that the even the less prevalent symptoms (eg, Swelling in Limbs, Problems With Urination, Pain During Sex, Weight Gain) were reported by more than one-quarter of the sample. Moreover, weight gain had the highest endorsement for desire for help among any of the symptoms experienced. This suggests that there may be a "teachable moment" for at least some breast cancer survivors with respect to health behaviors, 30 which is potentially important because weight relates to a number of indices of post-cancer QoL, 31 including survival, 32 and there are now indications that weight loss may reduce the side-effects of AIs as well. 33 Our data complement and extend those in the literature. Janz and colleagues 5 found a somewhat lower prevalence of symptoms (mean, 6.8) among a sample of breast cancer survivors following treatment, but this sample was limited to stage 0-II patients and collapsed symptoms into presumed categories (eg, "systemic side effects") making specific comparisons difficult. The most prevalent individual symptoms, however, were strikingly similar to those in the current study (ie, Feeling Tired, Needing Rest, Hot Flashes, and Pain). Cheng and colleagues 7 found that a similar set of symptoms (Lack of Energy, Numbness, Pain, Difficulty Sleeping, Worry) were prevalent (>29%) among breast cancer survivors. Moreover, findings from this study were very similar in terms of proportion of individuals reporting at least 1 unmet need (51%). The study by Cheng and colleagues 7 was limited by a wide cross-sectional range of time since treatment (6 months to 5 years) and of not inquiring about desire for help with specific symptoms. Although symptoms experienced by breast cancer survivors at the end of treatment have been examined in the literature, unmet need for assistance with those symptoms is not often explored.
This study has some limitations. Our sample was relatively small, although it is larger than other studies examining similar issues. 34, 35 In addition, although a sample of convenience, our participants were consecutive patients within a specified timeframe following treatment at a single facility and attending a survivorship visit, limiting generalizability. We believe that the symptoms and unmet needs for intervention likely represent what one could expect to encounter in a typical breast cancer survivorship clinical visit near end of treatment, but research using other samples (eg, registry based) would be needed to ensure this. We did not follow these participants over time, so it is not possible to ascertain if symptoms were recognized, intervention offered or accepted, and to what end. We are addressing this in ongoing research that utilizes an intervention to improve the recognition of unmet need with the use of an electronic PRO questionnaire in the patient's medical record, methods to facilitate remediation, and examination of associated outcomes.
Conclusion
Symptoms are common among recent breast cancer survivors and negatively impact QoL. Unmet needs and desire www.jcso-online.com
Original Report for help are less common, though similarly associated with impairment in QoL. The more severe symptoms seem to relate to receipt of AIs, suggesting that remediation could be important for maintaining adherence. Assessing symptom burden is important, but without assessing need for assistance it may miss important areas for which remediation is wanted and could result in improved QoL. Patient and provider education regarding the potential for and value of assessing unmet need may be needed in breast cancer survivors to improve quality of life outcomes.
